Literature DB >> 31680043

CFTR processing, trafficking and interactions.

Margarida D Amaral1, Darren M Hutt2, Valeria Tomati3, Hugo M Botelho1, Nicoletta Pedemonte4.   

Abstract

Mutations associated with cystic fibrosis (CF) have complex effects on the cystic fibrosis transmembrane conductance regulator (CFTR) protein. The most common CF mutation, F508del, disrupts the processing to and stability at the plasma membrane and function as a Cl- channel. CFTR is surrounded by a dynamic network of interacting components, referred to as the CFTR Functional Landscape, that impact its synthesis, folding, stability, trafficking and function. CFTR interacting proteins can be manipulated by functional genomic approaches to rescue the trafficking and functional defects characteristic of CF. Here we review recent efforts to elucidate the impact of genetic variation on the ability of the nascent CFTR polypeptide to interact with the proteostatic environment. We also provide an overview of how specific components of this protein network can be modulated to rescue the trafficking and functional defects associated with the F508del variant of CFTR. The identification of novel proteins playing key roles in the processing of CFTR could pave the way for their use as novel therapeutic targets to provide synergistic correction of mutant CFTR for the greater benefit of individuals with CF.
Copyright © 2019. Published by Elsevier B.V.

Entities:  

Keywords:  CFTR Cl-channel; CFTR correctors; CFTR functional landscape; CFTR interactome; F508del-CFTR; Proteostasis regulators; siRNA screening

Year:  2019        PMID: 31680043     DOI: 10.1016/j.jcf.2019.10.017

Source DB:  PubMed          Journal:  J Cyst Fibros        ISSN: 1569-1993            Impact factor:   5.482


  7 in total

1.  UPR modulation of host immunity by Pseudomonas aeruginosa in cystic fibrosis.

Authors:  Brahmchetna Bedi; Kuo-Chuan Lin; Nicholas M Maurice; Zhihong Yuan; Kaiser Bijli; Michael Koval; C Michael Hart; Joanna B Goldberg; Arlene Stecenko; Ruxana T Sadikot
Journal:  Clin Sci (Lond)       Date:  2020-07-31       Impact factor: 6.124

2.  SARS-CoV-2 (COVID-19) and cystic fibrosis.

Authors:  Bruce A Stanton; Thomas H Hampton; Alix Ashare
Journal:  Am J Physiol Lung Cell Mol Physiol       Date:  2020-07-15       Impact factor: 5.464

Review 3.  Small Hsps as Therapeutic Targets of Cystic Fibrosis Transmembrane Conductance Regulator Protein.

Authors:  Stéphanie Simon; Abdel Aissat; Fanny Degrugillier; Benjamin Simonneau; Pascale Fanen; André-Patrick Arrigo
Journal:  Int J Mol Sci       Date:  2021-04-20       Impact factor: 5.923

Review 4.  Proteostasis Regulators in Cystic Fibrosis: Current Development and Future Perspectives.

Authors:  Irene Brusa; Elvira Sondo; Federico Falchi; Nicoletta Pedemonte; Marinella Roberti; Andrea Cavalli
Journal:  J Med Chem       Date:  2022-04-04       Impact factor: 8.039

5.  The Effect of Sodium Bicarbonate, a Beneficial Adjuvant Molecule in Cystic Fibrosis, on Bronchial Epithelial Cells Expressing a Wild-Type or Mutant CFTR Channel.

Authors:  Ilona Gróf; Alexandra Bocsik; András Harazin; Ana Raquel Santa-Maria; Gaszton Vizsnyiczai; Lilla Barna; Lóránd Kiss; Gabriella Fűr; Zoltán Rakonczay; Rita Ambrus; Piroska Szabó-Révész; Fabien Gosselet; Pongsiri Jaikumpun; Hajnalka Szabó; Ákos Zsembery; Mária A Deli
Journal:  Int J Mol Sci       Date:  2020-06-04       Impact factor: 5.923

6.  Allosteric folding correction of F508del and rare CFTR mutants by elexacaftor-tezacaftor-ivacaftor (Trikafta) combination.

Authors:  Guido Veit; Ariel Roldan; Mark A Hancock; Dillon F Da Fonte; Haijin Xu; Maytham Hussein; Saul Frenkiel; Elias Matouk; Tony Velkov; Gergely L Lukacs
Journal:  JCI Insight       Date:  2020-09-17

Review 7.  Revisiting CFTR Interactions: Old Partners and New Players.

Authors:  Carlos M Farinha; Martina Gentzsch
Journal:  Int J Mol Sci       Date:  2021-12-07       Impact factor: 5.923

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.